Glaukos (GKOS) Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Glaukos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GKOS, but not buy additional shares or sell existing shares.
View analyst ratings for Glaukos or view top-rated stocks.

9 analysts have issued twelve-month price objectives for Glaukos' shares. Their GKOS stock forecasts range from $40.00 to $68.00. On average, they predict Glaukos' share price to reach $57.38 in the next year. This suggests a possible upside of 8.3% from the stock's current price.
View analysts' price targets for Glaukos or view top-rated stocks among Wall Street analysts.

Glaukos' stock was trading at $44.44 on January 1st, 2022. Since then, GKOS shares have increased by 19.2% and is now trading at $52.98.
View the best growth stocks for 2022 here.

Glaukos is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our earnings forecast for Glaukos.

Glaukos Co. (NYSE:GKOS) issued its earnings results on Thursday, November, 4th. The medical instruments supplier reported $0.13 EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.37. The medical instruments supplier earned $74.71 million during the quarter, compared to analyst estimates of $72.73 million. Glaukos had a negative net margin of 19.35% and a negative trailing twelve-month return on equity of 13.82%. The firm's revenue for the quarter was up 15.2% on a year-over-year basis. During the same period last year, the company posted ($0.09) EPS.

Glaukos updated its FY 2022 earnings guidance on Wednesday, August, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $275.00 million-$280.00 million, compared to the consensus revenue estimate of $274.39 million.

10 employees have rated Glaukos CEO Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among Glaukos' employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA).

(GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Glaukos' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (1.90%), Riverbridge Partners LLC (1.36%), Interwest Venture Management Co. (0.74%), Taylor Frigon Capital Management LLC (0.20%), State of New Jersey Common Pension Fund D (0.12%) and Granite Investment Partners LLC (0.10%). Company insiders that own Glaukos stock include Joseph E Gilliam, Thomas William Burns and William J Phd Link.
View institutional ownership trends for Glaukos.

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GKOS stock can currently be purchased for approximately $52.98.

Glaukos (NYSE:GKOS) has a market capitalization of $2.51 billion and generates $294.01 million in revenue each year. The medical instruments supplier earns $-49,590,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis.

Glaukos employs 727 workers across the globe.

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The official website for Glaukos is www.glaukos.com. The medical instruments supplier can be reached via phone at (949) 367-9600, via email at investors@glaukos.com, or via fax at 949-367-9984.